Impairment Risk for Goodwill and Intangible Assets at Overseas Subsidiaries
First written in FY2017. 7 of 9 entries say "Materialised", first in FY2018. Latest entry: FY2026.
ReproCELL moved to the "Worse" side of this theme in 2018, 4 years before the typical company in this theme (2022).
The whole theme swung hardest in 2026: 17 of 32 companies on the "Worse" side.
25 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「In addition, during the current consolidated fiscal year, the company determined that there were indications of impairment for the intangible fixed assets held by its medical business, because business performance had remained below the plan initially formulated.」
The company recognized an impairment loss of ¥6.055 million on software used in its medical business due to failure to meet plan, meaning that the impairment risk materialized. - 2026-05-14MaterialisedEarnings
「Consolidated fiscal year (from 1 April 2025 to 31 March 2026) (Unit: thousands of yen) Research Support business Medical business Corporate/eliminations Total Impairment loss — 6,055 — 6,055」
An impairment loss of ¥6.055 million was recognized in the Medical business. - FY2025MitigatedAnnual report
「In addition, during the current consolidated fiscal year, the company determined that there were no indications of impairment because no business had performed significantly below plan.」
Although overseas subsidiaries and others had incurred impairment losses through the previous fiscal year, the company determined that there were no indications of impairment during the current consolidated fiscal year because no business had performed significantly below plan. - FY2024MaterialisedAnnual report
「In addition, during the current consolidated fiscal year, the company determined that there were indications of impairment for the tangible fixed assets held by its research support business and by consolidated subsidiary Bioserve Biotechnologies India Pvt. Ltd. (India), because business performance had remained below the plans initially formulated.」
During the current fiscal year, the company identified indications of impairment for the tangible fixed assets of its Indian subsidiary and recognized an impairment loss of ¥50.676 million in total on machinery and equipment and tools, furniture and fixtures. - FY2023MaterialisedAnnual report
「In addition, during the current consolidated fiscal year, the company determined that there were indications of impairment for the tangible fixed assets held by its research support and medical businesses, because operating income and loss had remained negative, among other reasons.」
The company recognized an impairment loss of ¥131.613 million on assets used in its research support and medical businesses at headquarters, due to factors including failure to meet the business plans. The continuing impairment risk materialized during the current fiscal year as well. - FY2021MaterialisedAnnual report
「During the current consolidated fiscal year, the company determined that there were indications of impairment for the tangible fixed assets held by REPROCELL Europe Ltd. (United Kingdom), because the performance of its business had remained below the plan initially formulated.」
For REPROCELL Europe, the company recognized an impairment loss of ¥6.373 million on buildings and ¥16.834 million on tools, furniture and fixtures, for a total of ¥23.207 million, meaning that the impairment risk at an overseas subsidiary materialized during the current fiscal year as well. - FY2020MaterialisedAnnual report
「This resulted from a review of future business plans, taking into account such factors as business performance remaining below the plans initially formulated, and an examination of recoverable amounts.」
The company recognized an impairment loss of ¥115.879 million in total on goodwill and other assets relating to Bioserve Biotechnologies India, meaning that the impairment risk at an acquired subsidiary newly materialized. - FY2018MaterialisedAnnual report
「This resulted from a review of future business plans, taking into account such factors as business performance remaining below the plans initially formulated, and an examination of recoverable amounts.」
The company recognized an impairment loss of ¥1,324.614 million in total on goodwill and other assets relating to REPROCELL USA and REPROCELL Europe, meaning that the previously disclosed impairment risk materialized. - FY2017First statedAnnual report
「If the business plans of the subsidiaries do not progress as expected, there is a risk of impairment. Goodwill at Stemgent has already been impaired in the previous consolidated fiscal year, but the risk of impairment remains for the other goodwill balances.」
The company disclosed the impairment of goodwill and intangible assets resulting from acquired subsidiaries failing to meet their business plans, including the impairment already recognized at Stemgent and the remaining risk.